Skip to main content

Research Repository

Advanced Search

All Outputs (66)

High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition (2024)
Journal Article
James, D., Green, S., Molica, S., & Allsup, D. (2024). High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition. Case Reports in Hematology, 2024, Article 1813512. https://doi.org/10.1155/2024/1813512

The coexistence of chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) in the same patient is exceedingly rare, with only a few cases reported in the literature. Here, we report a patient with CML who, having achieved a major molecu... Read More about High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition.

Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia (2024)
Journal Article
Molica, S., Allsup, D., & Giannarelli, D. (online). Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia. American Journal of Hematology, https://doi.org/10.1002/ajh.27437

The emergence of Bruton's tyrosine kinase (BTK) inhibitors marked a significant advancement in chronic lymphocytic leukemia (CLL) management, especially for high-risk patients. 1 Ibrutinib, the pioneering BTK inhibitor, has undergone extensive study.... Read More about Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia.

Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia—a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial (2024)
Journal Article
Flett, L., Abdelatif, R., Akhtar Baz, S., Brady, S., Corbacho, B., Common, K., Cowling, A., Fairhurst, C., Fitzmaurice, E., Gandhi, S., Hilton, A., Hope, W., Howard, A., Laycock, J., Lillie, P., Mitchell, G., Parker, A., Peel, M., Sheard, L., Sneddon, J., …Barlow, G. (2024). Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia—a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial. Trials, 25(1), Article 427. https://doi.org/10.1186/s13063-024-08272-w

BACKGROUND: Acute leukaemias (AL) are life-threatening blood cancers that can be potentially cured with treatment involving myelosuppressive, multiagent, intensive chemotherapy (IC). However, such treatment is associated with a risk of serious infect... Read More about Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia—a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial.

Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population (2024)
Journal Article
Molica, S., Shanafelt, T. D., Allsup, D., & Giannarelli, D. (2024). Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population. Cancers, 16(6), Article 1085. https://doi.org/10.3390/cancers16061085

To assess the impact of first-line treatment with targeted agents (TAs) or fludarabine, cyclophosphamide, and rituximab (FCR)-based chemo-immunotherapy (CIT) on overall survival (OS) compared to age- and sex-matched individuals in the general populat... Read More about Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population.

How can we optimize antifungal use and stewardship in the treatment of acute leukemia? (2024)
Journal Article
Taynton, T., Allsup, D., & Barlow, G. (2024). How can we optimize antifungal use and stewardship in the treatment of acute leukemia?. Expert Review of Hematology, https://doi.org/10.1080/17474086.2024.2383401

Introduction: The global need for antifungal stewardship is driven by spreading antimicrobial and antifungal resistance. Triazoles are the only oral and relatively well-tolerated class of antifungal medications, and usage is associated with acquired... Read More about How can we optimize antifungal use and stewardship in the treatment of acute leukemia?.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease (2023)
Journal Article
Munir, T., Cairns, D. A., Bloor, A., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, J., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Walewska, R., Duley, L., Howard, D., …Hillmen, P. (2024). Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine, 390(4), 326-337. https://doi.org/10.1056/NEJMoa2310063

BACKGROUND: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment duration... Read More about Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials (2023)
Journal Article
Molica, S., & Allsup, D. (2023). Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials. Expert Review of Anticancer Therapy, https://doi.org/10.1080/14737140.2023.2288899

Introduction: Chronic lymphocytic leukemia (CLL) management has witnessed a transformative shift with the advent of time-limited venetoclax and anti-CD20 monoclonal antibody (mAb) regimens, as exemplified by the groundbreaking MURANO and CLL14 trials... Read More about Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials.

Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets (2023)
Journal Article
Gil, H. M., Booth, Z., Price, T. W., Lee, J., Naylor‐Adamson, L., Avery, M., Muravitskaya, A., Hondow, N., Allsup, D., Schneider, J. E., Naseem, K., Adawi, A. M., Bouillard, J. S. G., Chamberlain, T. W., Calaminus, S. D., & Stasiuk, G. J. (in press). Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets. Small, Article 2304881. https://doi.org/10.1002/smll.202304881

InP/ZnS quantum dots (QDs) have received a large focus in recent years as a safer alternative to heavy metal-based QDs. Given their intrinsic fluorescent imaging capabilities, these QDs can be potentially relevant for in vivo platelet imaging. The In... Read More about Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets.

Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (in press). Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions. Hematological Oncology, https://doi.org/10.1002/hon.3238

In the modern era of Chronic Lymphocytic Leukemia (CLL) targeted therapy, the loss of p53 function due to genetic abnormalities remains a significant challenge. This is because even targeted agents, which are currently the mainstay of treatment for C... Read More about Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL (2023)
Journal Article
Visentin, A., Chatzikonstantinou, T., Scarfò, L., Kapetanakis, A., Demosthenous, C., Karakatsoulis, G., ERIC Group, Minga, E., Chamou, D., Allsup, D., Cabrero, A. A., Andres, M., Antic, D., Baile, M., Baliakas, P., Besikli-Dimou, S., Bron, D., Chatzileontiadou, S., Cordoba, R., Correa, J. G., …Te Raa, D. (2023). The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL. American Journal of Hematology, 98(12), 1856-1868. https://doi.org/10.1002/ajh.27093

In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytos... Read More about The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.

Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide (2023)
Journal Article
Molica, S., Rossi, M., & Allsup, D. (2023). Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide. Acta Haematologica, 147(3), 257-259. https://doi.org/10.1159/000533349

In addition to the European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN) guidelines that are reference standards for the treatment of chronic lymphocytic leukemia (CLL) in Europe and the USA, several consensus... Read More about Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide.

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (2023). Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option. Cancers, 15(14), Article 3737. https://doi.org/10.3390/cancers15143737

Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL). The use of ibrutinib is, howev... Read More about Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial (2023)
Journal Article
Hillmen, P., Pitchford, A., Bloor, A., Broom, A., Young, M., Kennedy, B., Walewska, R., Furtado, M., Preston, G., Neilson, J. R., Pemberton, N., Sidra, G., Morley, N., Cwynarski, K., Schuh, A., Forconi, F., Elmusharaf, N., Paneesha, S., Fox, C. P., Howard, D. R., …Munir, T. (2023). Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The lancet oncology, 24(5), 535-552. https://doi.org/10.1016/S1470-2045%2823%2900144-4

Background: The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludara... Read More about Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies (2023)
Journal Article
Khan, S., Allsup, D., & Molica, S. (2023). An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies. Frontiers in Oncology, 13, Article 1135812. https://doi.org/10.3389/fonc.2023.1135812

Chronic lymphocytic leukaemia (CLL) is a malignancy of clonally expanded antigen-switched, neoplastic, mature B cells. CLL is characterised by a variable degree of immunosuppression and secondary hypogammaglobulinemia. B-cell depleting therapies have... Read More about An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies.

Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol (2023)
Journal Article
Baldwin, Z.-A., Busby, S., Allsup, D., Cohen, J., & Bamidele, O. (2023). Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol. PLoS ONE, 18(3), Article e0282458. https://doi.org/10.1371/journal.pone.0282458

Introduction Haematological malignancies are a heterogenous group of blood and lymphatic cancers. Survivorship care is a similarly diverse term concerning patients’ health and wellbeing from diagnosis to end of life. Survivorship care for patients wi... Read More about Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol.

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL (2022)
Journal Article
Antic, D., Milic, N., Chatzikonstantinou, T., Scarfò, L., Otasevic, V., Rajovic, N., Allsup, D., Alonso Cabrero, A., Andres, M., Baile Gonzales, M., Capasso, A., Collado, R., Cordoba, R., Cuéllar-García, C., Correa, J. G., De Paoli, L., De Paolis, M. R., Del Poeta, G., Dimou, M., Doubek, M., …Stamatopoulos, K. (2022). Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. Journal of Hematology & Oncology, 15(1), Article 116. https://doi.org/10.1186/s13045-022-01333-0

BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immu... Read More about Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.